Open navigation menu
Invest
Invest on your own
We do it for you
Halal tools
Screeners
Your portfolio
Calculators
Shariah
Our certifications
Learn
Education
Get help
News
Pricing
Company
About Musaffa
Investors
Build with us
Is Halozyme Therapeutics, Inc. Stock Halal?
Shariah Compliance Analysis of HALO Stock
United States Health Care Large Cap No. As of November 2026, Halozyme Therapeutics, Inc. (HALO) is classified as NOT HALAL by Musaffa under its AAOIFI-based Shariah screening methodology. Halozyme Therapeutics, Inc. does not pass Musaffa's business and financial screening criteria.
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. The company is headquartered in San Diego, California and currently employs 423 full-time employees. The company went IPO on 2003-01-30. The firm's commercially-validated solution, ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, is used to facilitate the subcutaneous delivery of injected drugs and fluids, with a focus on improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. The firm licenses its technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with its partners’ proprietary compounds. The company also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The firm has two commercial proprietary products, Hylenex and XYOSTED. The company also has a proprietary ultra-high concentration microparticle formulation technology for biologics, branded Hypercon.
HALO Shariah Compliance
Screening Methodology: AAOIFI
As of November 2026, Halozyme Therapeutics, Inc. is classified as not halal.
NOT HALALHalozyme Therapeutics, Inc. (HALO) Chart
Fetching Price Chart...
Financial Metrics & Statements of Halozyme Therapeutics, Inc. (HALO)
FAQ's for Halozyme Therapeutics, Inc. (HALO)
- As of November 2026, Halozyme Therapeutics, Inc. HALO is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Halozyme Therapeutics, Inc. using these criteria to determine its compliance status.
- Muslim investors may consider investing in Halozyme Therapeutics, Inc. if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Halozyme Therapeutics, Inc. by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Halozyme Therapeutics, Inc. may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Halozyme Therapeutics, Inc. on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for Halozyme Therapeutics, Inc. (HALO)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
